Ptc Therapeutics (PTCT) Other Non-Current Liabilities (2012 - 2026)

Ptc Therapeutics' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $13.7 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $13.7 million in Q1 2026; TTM through Mar 2026 was $13.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $13.7 million, up 1613.0% from the prior year.
• Other Non-Current Liabilities held at $13.7 million in Q1 2026 per PTCT's latest filing, from $13.7 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $228.2 million in Q1 2022 and bottomed at $77000.0 in Q3 2024.
• The 5-year median for Other Non-Current Liabilities is $3.6 million (2022), against an average of $39.7 million.
• Across the five-year window, Other Non-Current Liabilities tumbled 99.94% in 2023 and soared 25573.76% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $164.0 million in 2022, then plunged by 99.91% to $141000.0 in 2023, then soared by 467.38% to $800000.0 in 2024, then jumped by 1613.0% to $13.7 million in 2025, then changed by 0.0% to $13.7 million in 2026.
• Per Business Quant, the three latest PTCT Other Non-Current Liabilities figures stand at $13.7 million (Q1 2026), $13.7 million (Q4 2025), and $2.6 million (Q3 2025).